Vaishnav J, Brown E, Sharma K. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy. Prog Cardiovasc Dis. 2024;82:113–24.

Article  PubMed  Google Scholar 

Zhou S, Ge S, Zhang W, et al. Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis. ACS Chem Neurosci. 2020;11(19):3025–35.

Article  CAS  PubMed  Google Scholar 

Miller M, Pal A, Albusairi W, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61(17):7862–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

BridgeBio Pharma, Inc,. Attruby™ (acoramidis), a near complete TTR stabilizer (≥90%), approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients [media release]. Nov 22 2024. https://bridgebio.com

BridgeBio Pharma, Inc,. ATTRUBY™ (acoramidis) tablets, for oral administration. US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf. Accessed Nov 29, 2024

BridgeBio Pharma, Inc,. Form 10-Q for the quarterly period ended September 30, 2024. SEC Filing Report 2024.

BridgeBio Pharma, Inc,. Form 10-K for fiscal year ended December 31, 2023. SEC Filing Report 2023.

BridgeBio Pharma, Inc,. BridgeBio Pharma, Inc. announces completion of merger with Eidos Therapeutics, Inc [media release]. 26 Jan 2021. https://bridgebio.com

Alexion Pharmaceuticals. Alexion and BridgeBio announce Japanese license agreement for Eidos' transthyretin amyloidosis (ATTR) investigational medicine [media release]. 9 Sep 2019. https://alexion.com

BridgeBio Pharma, Inc,. BridgeBio Pharma and Bayer announce European licensing agreement for acoramidis in ATTR-CM [media release]. 4 Mar 2024. https://bridgebio.com

Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–95.

Article  CAS  PubMed  Google Scholar 

Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132–42.

Article  CAS  PubMed  Google Scholar 

Verbeeck J, De Backer M, Buyse M. Acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(14):1345–6.

Article  PubMed  Google Scholar 

Hanna MH, Arad MA, Gonzalez-Juanatey J, et al. Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study. Eur J Heart Fail. 2024;26(S2):498.

Google Scholar 

Fontana M, Sperry BS, Kastritis EK, et al. Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores. Eur J Heart Fail. 2024;26(S2):497.

Google Scholar 

Razvi Y, Judge DP, Martinez-Naharro A, et al. Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy. Circ Heart Fail. 2024;17(12): e012135.

Article  PubMed  PubMed Central  Google Scholar 

Judge DP, Gillmore JD, Alexander KM, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial [online ahead of print]. Circulation. 2024. https://doi.org/10.1161/CIRCULATIONAHA.124.072771.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Beyonttra. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/beyonttra. Accessed 2024.